These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38371197)

  • 21. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
    Contieri R; Hurle R; Paciotti M; Casale P; Saita A; Porpiglia F; Fiori C; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Cantiello F; Damiano R; Borghesi M; Bove P; Bertolo R; Papalia R; Mari A; Luzzago S; Mistretta FA; Soria F; Gontero P; Marchioni M; LA Civita E; Terracciano D; Russo GI; Schips L; Perdona S; Mirone V; Tataru OS; Musi G; Vartolomei MD; Autorino R; Montanari E; DE Cobelli O; Ferro M
    Minerva Urol Nephrol; 2023 Apr; 75(2):180-187. PubMed ID: 36197700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.
    Hensley PJ; Bree KK; Brooks N; Matulay J; Li R; Nogueras-Gonzalez GM; Nagaraju S; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2022 Jun; 5(3):347-356. PubMed ID: 33935020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.
    Plasek J; Weissert J; Downs T; Richards K; Ravvaz K
    JMIR Cancer; 2021 Jun; 7(2):e25800. PubMed ID: 34156341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
    Lobo N; Bree KK; Hensley PJ; Nogueras-Gonzalez GM; Abraham P; Navai N; Dinney CP; Kamat AM
    BJU Int; 2022 Sep; 130(3):323-330. PubMed ID: 34847263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
    Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.
    van Straten CGJI; Caris C; Grimm MO; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Witjes WPJ; van der Heijden AG; Kiemeney LALM
    Eur Urol Open Sci; 2023 Oct; 56():15-24. PubMed ID: 37822514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
    Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
    Eur Urol Oncol; 2024 Dec; 7(6):1367-1375. PubMed ID: 38355375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.
    Rieken M; Shariat SF; Kluth L; Crivelli JJ; Abufaraj M; Foerster B; Mari A; Ilijazi D; Karakiewicz PI; Babjuk M; Gönen M; Xylinas E
    Urol Oncol; 2018 Jan; 36(1):8.e17-8.e24. PubMed ID: 28947304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
    Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
    Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
    van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
    Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G
    Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder.
    Krajewski W; Rodríguez-Faba O; Breda A; Pisano F; Poletajew S; Tukiendorf A; Zdrojowy R; Kołodziej A; Palou J
    Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):445-451. PubMed ID: 31155372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
    Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K
    Eur Urol Oncol; 2024 Aug; 7(4):760-769. PubMed ID: 37884420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    Miyake M; Iida K; Nishimura N; Miyamoto T; Fujimoto K; Tomida R; Matsumoto K; Numakura K; Inokuchi J; Morizane S; Yoneyama T; Matsumura Y; Abe T; Inoue M; Yamada T; Terada N; Hirao S; Uemura M; Matsushita Y; Taoka R; Kobayashi T; Kojima T; Matsui Y; Kitamura H; Nishiyama H;
    BMC Cancer; 2021 Mar; 21(1):266. PubMed ID: 33706705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.